Literature DB >> 9810003

Differences in susceptibility to tumor necrosis factor alpha-induced apoptosis among MCF-7 breast cancer cell variants.

M E Burow1, C B Weldon, Y Tang, G L Navar, S Krajewski, J C Reed, T G Hammond, S Clejan, B S Beckman.   

Abstract

Widespread use of MCF-7 human breast carcinoma cells as a model system for breast cancer has led to variations in these cells between different laboratories. Although several reports have addressed these differences in terms of proliferation and estrogenic response, variations in sensitivity to apoptosis have not yet been described. Tumor necrosis factor alpha (TNF-alpha) has been shown to both induce apoptosis and inhibit proliferation in MCF-7 cells. We observed that TNF-alpha inhibited proliferation in MCF-7 cell variants from three different laboratories (designated M, L, and N). MCF-7 M cells were resistant to TNF-alpha-induced apoptosis, whereas MCF-7 L cells were moderately resistant to the effect of TNF-alpha. A third variant, MCF-7 N, underwent apoptosis when exposed to TNF-alpha. Analysis of the p55 TNF-alpha receptor (TNFR) 1 expression revealed the greatest expression in MCF-7 N cells, whereas the MCF-7 L and M cells expressed 89 and 67% of MCF-7 N cell TNFR1 levels, respectively. Ceramide generation occurred in all three variants in response to TNF-alpha treatment, with MCF-7 N cells expressing the greatest increase. Cleavage of the CPP32/caspase 3 substrate poly(ADP-ribose) was observed in MCF-7 N and L cells as early as 3 and 6 h, respectively, but poly(ADP-ribose) cleavage was not observed in MCF-7 M cells. The delayed protease activation in the L variant may represent the mechanism by which these cells display delayed sensitivity to TNF-a-induced apoptosis. Expression of the Bcl-2, Mcl-1, Bcl-X, Bax, and Bak proteins was analyzed to determine whether the differences in MCF-7 cell sensitivity to apoptosis could be correlated to the differential expression of these proteins. Whereas Bak, Bcl-X, and Mcl-1 levels were identical between variants, the levels of Bcl-2 were 3.5-3.8-fold higher and the levels of Bax were 1.5-1.7-fold lower in the resistant variants (M and L) as compared with those of the sensitive variant (N). Taken together, these results suggest that differences in susceptibility to TNF-alpha-induced apoptosis among MCF-7 breast cancer cell variants may be explained by differences in TNFR expression, ceramide generation, differential expression of the Bcl-2 family of proteins, and protease activation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9810003

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Is tartrazine really safe? In silico and ex vivo toxicological studies in human leukocytes: a question of dose.

Authors:  Jassana Moreira Floriano; Emanoeli da Rosa; Queila Daiane Fonseca do Amaral; Luísa Zuravski; Pamella Eduardha Espindola Chaves; Michel Mansur Machado; Luís Flávio Souza de Oliveira
Journal:  Toxicol Res (Camb)       Date:  2018-07-20       Impact factor: 3.524

2.  Tumor cell apoptosis polarizes macrophages role of sphingosine-1-phosphate.

Authors:  Andreas Weigert; Nico Tzieply; Andreas von Knethen; Axel M Johann; Helmut Schmidt; Gerd Geisslinger; Bernhard Brüne
Journal:  Mol Biol Cell       Date:  2007-07-25       Impact factor: 4.138

3.  Role of p53, PUMA, and Bax in wogonin-induced apoptosis in human cancer cells.

Authors:  Dae-Hee Lee; Clifford Kim; Lin Zhang; Yong J Lee
Journal:  Biochem Pharmacol       Date:  2008-02-29       Impact factor: 5.858

4.  Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer.

Authors:  Lyndsay V Rhodes; Sarah P Short; Nicole F Neel; Virgilio A Salvo; Yun Zhu; Steven Elliott; Yongkun Wei; Dihua Yu; Menghong Sun; Shannon E Muir; Juan P Fonseca; Melyssa R Bratton; Chris Segar; Syreeta L Tilghman; Tammy Sobolik-Delmaire; Linda W Horton; Snjezana Zaja-Milatovic; Bridgette M Collins-Burow; Scott Wadsworth; Barbara S Beckman; Charles E Wood; Suzanne A Fuqua; Kenneth P Nephew; Paul Dent; Rebecca A Worthylake; Tyler J Curiel; Mien-Chie Hung; Ann Richmond; Matthew E Burow
Journal:  Cancer Res       Date:  2010-12-01       Impact factor: 12.701

5.  Inhibition of p38-MAPK alters SRC coactivation and estrogen receptor phosphorylation.

Authors:  James W Antoon; Melyssa R Bratton; Lori M Guillot; Scott Wadsworth; Virgilio A Salvo; Matthew E Burow
Journal:  Cancer Biol Ther       Date:  2012-07-24       Impact factor: 4.742

6.  Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.

Authors:  James W Antoon; Martin D White; William D Meacham; Evelyn M Slaughter; Shannon E Muir; Steven Elliott; Lyndsay V Rhodes; Hasina B Ashe; Thomas E Wiese; Charles D Smith; Matthew E Burow; Barbara S Beckman
Journal:  Endocrinology       Date:  2010-09-22       Impact factor: 4.736

7.  Effects of human mesenchymal stem cells on ER-positive human breast carcinoma cells mediated through ER-SDF-1/CXCR4 crosstalk.

Authors:  Lyndsay V Rhodes; James W Antoon; Shannon E Muir; Steven Elliott; Barbara S Beckman; Matthew E Burow
Journal:  Mol Cancer       Date:  2010-11-18       Impact factor: 27.401

8.  Proinflammatory cytokines tumor necrosis factor-alpha and interferon-gamma alter tight junction structure and function in the rat parotid gland Par-C10 cell line.

Authors:  Olga J Baker; Jean M Camden; Robert S Redman; Jonathan E Jones; Cheikh I Seye; Laurie Erb; Gary A Weisman
Journal:  Am J Physiol Cell Physiol       Date:  2008-09-03       Impact factor: 4.249

9.  Rapid activation of ERK1/2 and AKT in human breast cancer cells by cadmium.

Authors:  Zhiwei Liu; Xinyuan Yu; Zahir A Shaikh
Journal:  Toxicol Appl Pharmacol       Date:  2007-12-27       Impact factor: 4.219

10.  Tyrosine nitration of IkappaBalpha: a novel mechanism for NF-kappaB activation.

Authors:  Vasily A Yakovlev; Igor J Barani; Christopher S Rabender; Stephen M Black; J Kevin Leach; Paul R Graves; Glen E Kellogg; Ross B Mikkelsen
Journal:  Biochemistry       Date:  2007-10-02       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.